Parkinson's disease (PD) has been a widely known debilitative neurodegenerative condition affecting millions of people worldwide. While it's often mistakenly assumed to be a fatal illness, Parkinson's disease isn't fatal per se, it rather significantly impairs an individual's quality of life and exposes one to increased risk of developing complications that potentially lead to death.

Parkinson's disease develops when a part of the brain that is in charge of creating dopamine starts to break down. Dopamine is necessary for controlling movement and coordination. When these neurons are lost, characteristic symptoms like tremors, stiffness, slowness of movement, balance problems, and eventually mental and emotional changes develop. These symptoms can worsen over time and disrupt daily life.

Importantly, Parkinson's itself is not a death sentence. Rather, patients tend to experience an increased risk of complications—such as infections, pneumonia, or serious injuries from falls—that are lethal. Falls are among the top causes of Parkinson's-related fatalities, especially in advanced stages of the disease, the American Parkinson Disease Association reports.

Access to current medication, early diagnosis, successful therapy, and a network of supportive care can enable people with Parkinson's to live long and satisfied lives.

How Stem Cell Therapy Can Help Slow down Disease progression?

A recent phase 1 clinical trial published in Nature represents a breakthrough in the treatment of Parkinson's. The research, which took place at several sites in the US and Canada, employed stem cell–derived dopamine-producing neurons to attack the cause of Parkinson's—dopamine depletion.

Conceived in Dr. Lorenz Studer's and Dr. Viviane Tabar's laboratory at Memorial Sloan Kettering, the therapy works by reprogramming embryonic stem cells to become specialized nerve cells. Those cultured cells, or bemdaneprocel, are inserted into the Parkinson's patients' brains. Implanted, they start producing dopamine, which revitalizes some of the lost ability of the brain.

Twelve patients underwent this novel therapy, and at the end of 18 months, the outcomes were encouraging- the cells implanted had taken well within the brain.

No one reported severe side effects.

A few patients even evidenced stabilization or improvement of their symptoms.

This is an outstanding result given the failures of past attempts to replace damaged brain cells—such as fetal tissue implants in the 1980s—often resulted in inconsistent benefits and problematic side effects like dyskinesia (spontaneous movement).

With the promising phase 1 results, the U.S. Food and Drug Administration (FDA) has approved a phase 3 trial, which will start in 2025. The trial will involve around 100 patients and a control group that will receive a placebo, so that researchers can more accurately measure the actual effectiveness of the treatment.

One of the trial's lead investigators, Dr. Tabar, was quick to point out the wider implications of the study:

"This is a significant milestone on the journey toward regenerative brain repair. It may sound strange for a cancer center to be working on regenerative medicine for a neurodegenerative disease, but if we can learn how to replace cells that are lost due to disease in the brain and restore circuitry, we can apply it to other therapies—and eventually cancer patients will be the beneficiaries."

Five Stages of Parkinson's

Parkinson's disease is normally outlined in five stages, which describe a series of worsening symptoms:

Stage 1: Minimal symptoms with minimal to no interference with day-to-day activities. Early signs and symptoms are tremors, minimal posture changes, or slight movement abnormalities.

Stage 2: Moderate symptoms become more apparent and can start to impact everyday activities, such as speech and muscle coordination.

Stage 3: Balance and movement issues escalate. Falls are more common, although people still maintain independence.

Stage 4: Symptoms are severely restrictive, and patients frequently need help with simple tasks. The risk of injury from falls significantly increases.

Stage 5: The most advanced stage, characterized by an inability to walk or stand without support. Full-time care is needed, and patients are increasingly at risk of hallucinations, delusions, and infections that can be life-threatening.

Even with the progression of the disease, numerous individuals with Parkinson's live to near-normal life expectancy, provided there is good control of symptoms and medical care.

Though Parkinson's is still an incurable disease, stem cell therapy represents a hopeful therapeutic path that extends beyond the treatment of symptoms—it seeks cellular repair and regenerative healing. By directly targeting dopamine loss, this development has the potential to slow or even reverse some of the functional deficits resulting from the disease.

Patients taking a widely used blood pressure drug are being advised to verify their medication after a batch was recalled due to incorrect dosage information printed on the packaging. According to the Medicines and Healthcare Products Regulatory Agency (MHRA), some packs of lercanidipine, manufactured by Recordati Pharmaceuticals, have been wrongly labelled as containing 10mg tablets, when in fact they contain 20mg tablets.

Over 7000 Packs Are Subject To Recall

More than 7,700 packs already distributed are now subject to the recall, the MHRA has confirmed. Patients who may have the mislabelled medication are being urged to contact their GP, pharmacist, or call NHS 111 for advice. The NHS warns that consuming an excessive dose of lercanidipine can lead to symptoms such as dizziness and drowsiness. The MHRA issued the alert on Thursday after being informed by the Italian pharmaceutical company Recordati that the error was confined to a single batch of lercanidipine, which was initially distributed on April 10. The recalled packs carry the batch number MD4L07 and are marked with an expiry date of January 2028.

Although the front of the affected packs displays the incorrect strength, the correct 20mg dose is printed on the blister strips inside and on the side of some of the boxes. The MHRA advises patients who have been prescribed the 20mg dose to check the blister packaging to ensure they have received the correct medication. However, those prescribed 10mg tablets should seek immediate medical attention if they have this batch.

As a temporary measure, the MHRA suggests that patients who cannot reach a healthcare provider may take half of a 20mg tablet until they receive professional guidance. Dr Alison Cave, the MHRA’s chief safety officer, stated: "Healthcare professionals such as pharmacists are also being asked to stop supplying medicine from the affected batch and to return it to the supplier." She encouraged anyone experiencing suspected side effects to report them through the MHRA’s Yellow Card scheme.

In a statement to the BBC, a spokesperson for Recordati said the company is "working proactively" with the MHRA and will contact all customers who might have received the affected batch. “We are investigating the root cause and continue to work with our partners to isolate the issue and minimise disruption to our patients. Patient safety remains our top priority,” the spokesperson added.

What Do We Know About Lercanidipine?

Lercanidipine is used in the treatment of Angina (heart-related chest pain), Hypertension (high blood pressure), Arrhythmia, hypertensive emergency, subarachnoid haemorrhage and anal fissure. According to the NHS, it is one of the four types of blood pressure medicines sold across the UK. These pills are a calcium channel blocker. That means it regulates blood pressure by relaxing blood vessels and reducing pressure on them, thereby making it easier for the heart to pump more blood throughout the body. In this way, it normalises the blood pressure in patients with high blood pressure.

ALSO READ: RFK Jr.'s Autism Controversial Comments Face Backlash From Parents And Medical Experts

Robert F. Kennedy Jr., the U.S. Secretary of Health and Human Services, is facing strong backlash after making sweeping comments during a recent press conference regarding autism and its supposed causes. As the CDC released a report revealing a rise in autism diagnoses among U.S. children now affecting 1 in 31 8-year-olds Kennedy doubled down on discredited theories linking autism to environmental exposures and vaccines, while portraying the disorder in stark, stigmatizing terms.

His remarks including claims that children with autism “will never hold a job,” “never pay taxes,” or “never use a toilet unassisted”, were swiftly condemned by parents, medical experts, and advocacy groups alike for reinforcing outdated stereotypes and misrepresenting the broad and diverse autism spectrum.

Autism spectrum disorder (ASD) is not a single condition with uniform symptoms or outcomes. Rather, it is a neurological and developmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. The key word is "spectrum" and it exists for a reason.

Some individuals with autism may be nonverbal and need lifelong support, while others live independently, excel in careers, write books, or even hold public office. “Autism is not a disease,” said actress and autism advocate Holly Robinson Peete in a video statement, responding to Kennedy. “It is a developmental difference and it is important to get that right.”

Her son, RJ, diagnosed 25 years ago, has “shattered a lot of 'never' off that list,” she said, referring to Kennedy’s grim portrayal. Countless parents echoed this sentiment on social media, stating that Kennedy’s generalizations erase the lived realities, milestones, and accomplishments of their children.

CDC Data Shows a Rise in Diagnoses

The CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network reported that 1 in 31 8-year-olds in the U.S. were diagnosed with autism in 2022, compared to 1 in 54 in 2016. But experts stress that this increase is not necessarily cause for alarm. It is, in fact, a sign of progress.

The rise in autism rates is driven largely by improved awareness, broader diagnostic criteria, and increased access to evaluations and services. We are identifying children earlier and more accurately that’s a good thing.

Kennedy, however, rejected this explanation as “indefensible” and announced plans for a directive to the National Institutes of Health to investigate “environmental exposures” as the root cause — reigniting long-debunked concerns about vaccines and toxins.

Despite overwhelming scientific consensus debunking any link between vaccines and autism, Kennedy has long been associated with promoting vaccine hesitancy. His latest comments, veiled in language about “environmental exposures,” once again hint at this discredited narrative.

Leading medical organizations, including the American Academy of Pediatrics and the World Health Organization, have repeatedly emphasized that vaccines are safe, effective, and have no causal relationship with autism. Resurrecting these claims only spreads fear and confusion. It undermines public health and harms autistic people by framing their existence as a preventable tragedy.

Parents Demand a Shift in the Narrative

Perhaps the strongest rebuke came from parents of autistic children themselves. Samantha Taylor, whose 20-year-old son is on the spectrum, told Good Morning America, “Autism doesn’t destroy families misinformation does.” In a viral Facebook post, she added, “What truly causes damage is the relentless portrayal of autism as something catastrophic, rather than a different way of experiencing the world.”

Kennedy’s comments, they say, not only ignore the complexity of the condition but strip children of their dignity and potential.

“Statements like ‘they’ll never write a poem’ deny the creative genius that so many autistic individuals demonstrate,” said Peete. “It’s dangerous, it’s harmful, and it’s simply false.”

Experts Call for More Informed Leadership

While Kennedy has promised answers by September through federally backed studies, medical experts warn that his rhetoric may set back years of advocacy and research by framing autism as an “epidemic” akin to an infectious disease.

Autism is not something to be eradicated, it’s something to be understood, supported, and embraced. Families deserve resources, not fearmongering.

In the last two decades, the medical community has shifted toward neurodiversity — a perspective that recognizes neurological differences like autism as natural variations of the human genome. This philosophy emphasizes inclusivity, respect, and strength-based approaches rather than medicalizing difference.

At a time when public trust in institutions is fragile, the words of public officials matter deeply. Kennedy’s comments have triggered a reckoning not only about how autism is portrayed in the media and politics but also about how society chooses to value — or devalue — people who are different.

Advocates stress the need for policies rooted in science, not stigma, and for leadership that uplifts rather than marginalizes.

As the national conversation around autism continues, one thing is clear: the autism community — parents, children, adults on the spectrum, clinicians, and allies — is not going to stay silent in the face of outdated narratives.

On World Liver Day, which is observed on April 19, to spread awareness about liver health and the life-saving power of organ donation, let us look at one such real-life story. This is where doctor's prompt's action and one's selfless donation saved one human's life.

When the 30-year-old Delhi-based man walked into the hospital, he had yellow eyes and dangerously high liver enzymes. He was admitted in Max Super Speciality Hospital, Patparganj. That moment, he rarely knew that his life was, in fact, hanging by a thread. The man was diagnosed with acute liver failure, which was caused by viral hepatitis. His body was slowly shutting down. The frequency of his body shutting down had increased. The doctors also quickly informed the family. This was the one last hope of survival - a liver transplant.

The First Option Failed

His sister was family's first ray of hope. She was also willing and had a compatible liver whose part of it could be donated. However, pre-surgery tests revealed that her liver size was too small to ensure a safe transplant. The family then proposed the patient's brother-in-law - a second-degree relative, as the next donor. His liver was a better match, but since he was not an immediate blood relative, there had to be special regulatory approvals which were required.

However, the worsening condition of the patients allowed no such time.

The hospital too scrambled to get clearance for the brother-in-law. All this while, the patient suffered a cardiac arrest. The situation turned dire within minutes. Doctors performed CPR to revive him. He was immediately put on ventilator support. The decision had to be taken soon.

A Miraculous Surgery

With no time in hand, the doctors decided to go ahead with the sister as the donor, though there were risks there too.

A team of highly skilled hepatobiliary surgeons, anesthesiologists, and critical care specialists took over. In a high-risk, nine-hour surgery, they removed the patient’s failing liver and replaced it with part of his sister’s.

“This was one of the most challenging cases we’ve handled,” said Dr. Ajitabh Srivastava, Director – HPB Surgery & Liver Transplant. “When the patient collapsed, our team acted within seconds. Every decision, every move mattered. His survival was truly a team triumph.”

The patient is now recovering well.

What Is A Liver Transplant?

As per the National Institute of Diabetes and Digestive and Kidney Diseases, a liver transplant is a surgical procedure to replace a diseased liver with a healthy one from a donor. It’s often the last resort when liver failure occurs—whether due to chronic illness or sudden injury.

When Is It Needed?

People may need a liver transplant for:

• Alcoholic liver disease
• Fatty liver disease (NASH)
• Cirrhosis due to chronic hepatitis C
• Liver cancer with cirrhosis
• Acute liver failure (often due to drug overdose, hepatitis, or toxins)

In children, biliary atresia is the most common reason.

Types of Liver Transplants

Deceased Donor Transplant:

The most common type, where a full or partial liver is taken from someone who has recently died.

Living Donor Transplant:

A healthy person donates a portion of their liver—typically a close relative. Both the donor’s and recipient’s liver regenerate to normal size in a few weeks.

What Must Be Kept In The Mind?

• Matching and Compatibility: Blood type, liver size, and health are crucial.
• Approval Process: Especially important for non-blood relatives.
• Recovery and Monitoring: Post-op care involves lifelong medication, lifestyle changes, and regular check-ups.